BioPharmSignal logoBioPharmSignal

Biotech News

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Phathom Pharmaceuticals (PHAT)Phathom PharmaceuticalsClinical readout

Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first quarter of 2028 pHalcon-NERD-302, if successful, is intended to support a

Related news

PHATPhathom Pharmaceuticals2026-06-23 11:59 EST

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

PHATPhathom Pharmaceuticals2026-05-01 12:00 EST

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

View all latest news

Phathom Pharmaceuticals

Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker. VOQUEZNA Franchise VOQUEZNA is marketed in the United States for heartburn associated with non-erosive...

Recent company news

PHATPhathom Pharmaceuticals2026-09-29 12:00 EST

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

PHATPhathom Pharmaceuticals2026-09-01 12:00 EST

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

PHATPhathom Pharmaceuticals2026-07-30 10:59 EST

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

PHATPhathom Pharmaceuticals2026-07-20 12:00 EST

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

PHATPhathom Pharmaceuticals2026-06-23 11:59 EST

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Stock data

Close
7.08 USD
Market cap
769.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States